RPESCRPE 4W
Alternative Names: RPESC-RPE-4WLatest Information Update: 24 Apr 2023
At a glance
- Originator Neural Stem Cell Institute
- Developer Luxa Biotechnology
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Dry age-related macular degeneration
Most Recent Events
- 20 Apr 2023 Pharmacodynamics data from a preclinical trial in Age-related macular degeneration released by Luxa Biotechnology
- 21 Apr 2022 Phase-I/II clinical trials in Dry age-related macular degeneration (In adults, In the elderly) in USA (Parenteral) (NCT04627428)
- 13 Nov 2020 Luxa Biotechnology plans a phase I/IIa trial for Dry age-related macular degeneration in USA in May 2021 (NCT04627428)